SpringWorks Therapeutics, Inc. (SWTX)
Jul 1, 2025 - SWTX was delisted (reason: acquired by Merck KGaA)
46.99
0.00 (0.00%)
Inactive · Last trade price on Jun 30, 2025

Company Description

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer.

It offers OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor for the treatment of desmoid tumors; and GOMEKLI (mirdametinib), an oral small molecule inhibitor of MEK1 and MEK2 for the treatment of adult and pediatric patients two years of age and older with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN).

The company also develops Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer; and mirdametinib for the treatment of solid tumors harboring other MAPK aberrations, including for the treatment of pediatric and young adult patients with low-grade gliomas that is in Phase 1/2 clinical trial.

In addition, its products under development include Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations.

The company has license agreements with Pfizer Inc. for nirogacestat and mirdametinib; and Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain.

SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut. As of July 1, 2025, SpringWorks Therapeutics, Inc. operates as a subsidiary of Merck KGaA.

SpringWorks Therapeutics, Inc.
SpringWorks Therapeutics logo
CountryUnited States
Founded2017
IPO DateSep 13, 2019
IndustryBiotechnology
SectorHealthcare
Employees368
CEOSaqib Islam

Contact Details

Address:
100 Washington Boulevard
Stamford, Connecticut 06902
United States
Phone203 883 9490
Websitespringworkstx.com

Stock Details

Ticker SymbolSWTX
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$18.00
CIK Code0001773427
CUSIP Number85205L107
ISIN NumberUS85205L1070
Employer ID94-2551470
SIC Code3081

Key Executives

NamePosition
Saqib Islam J.D.Chief Executive Officer and Director
Francis I. Perier Jr., M.B.A.Chief Financial Officer
Dr. Badreddin Edris Ph.D.Chief Operating Officer
Bhavesh Ashar M.B.A.Chief Commercial Officer
Dr. James Cassidy M.D., Ph.D.Chief Medical Officer
Michael P. NofiChief Accounting Officer
Tai-An Lin Ph.D.Chief Scientific Officer
Kim DiamondVice President of Communications and Investor Relations
Herschel S. Weinstein J.D.General Counsel and Secretary
Daniel J. PichlChief People Officer

Latest SEC Filings

DateTypeTitle
Dec 9, 2011SC 13D/A[Amend] General statement of acquisition of beneficial ownership
Dec 9, 201115-12BSecurities registration termination
Dec 6, 2011S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Dec 6, 2011S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Dec 6, 2011S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Dec 6, 2011S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Dec 6, 2011S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Dec 6, 2011S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Dec 6, 2011S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Dec 6, 2011S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments